DNA methylation of the protein-tyro sine phosphatase SHP1 in Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML).

被引：0
|
作者：
Hoshino, K
Yang, H
Canalli, AA
Sanchez-Gonzalez, B
Donato, N
Kantarjian, H
Issa, JP
Garcia-Manero, G
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1528
引用
收藏
页码：420A / 421A
页数：2
相关论文
共 50 条
  • [31] PHILADELPHIA-CHROMOSOME (PH1)-NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA (CML) - A CLONAL DISEASE WITH ORIGIN IN A MULTIPOTENT STEM-CELL
    FIALKOW, PJ
    JACOBSON, RJ
    SINGER, JW
    SACHER, RA
    MCGUFFIN, RW
    NEEFE, JR
    BLOOD, 1980, 56 (01) : 70 - 73
  • [32] MOLECULAR STUDY OF THE PHILADELPHIA (PH1) TRANSLOCATION IN CHRONIC MYELOGENOUS LEUKEMIA (CML) IN DIFFERENT STAGES OF THE DISEASE
    SELLERI, L
    EMILIA, G
    NARNI, F
    VENTURELLI, D
    DONELLI, A
    ZUCCHINI, P
    COLO, S
    GRASSILLI, E
    TORELLI, U
    TORELLI, G
    ACTA HAEMATOLOGICA, 1987, 78 : 205 - 205
  • [33] Sequential homoharringtonine (HHT) and interferon (IFN-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML).
    O'Brien, S
    Kantarjian, H
    Koller, C
    Andreeff, M
    Feldman, E
    Keating, M
    Beran, M
    Freireich, E
    Rios, MB
    Talpaz, M
    BLOOD, 1998, 92 (10) : 656A - 656A
  • [34] Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph(1)-positive chronic myelogenous leukemia
    Izumi, T
    Imagawa, S
    Hatake, K
    Miura, Y
    Ariyama, T
    Inazawa, J
    Abe, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1996, 64 (01) : 73 - 77
  • [35] Discovery of a Selective PROTAC Degrading Untamable BCR::ABL1 Compound Mutants in Chronic Myelogenous Leukemia (CML)and Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Rouhimoghadam, Milad
    Tang, Hua
    Bates, Briana
    Liao, Junzhuo
    Uribe-Cano, Daniela
    Tang, Weiping
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S336 - S336
  • [36] Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia
    Richardson, Matthew W.
    Grewal, Satkiran S.
    PEDIATRIC BLOOD & CANCER, 2008, 50 (01) : 186 - 186
  • [37] PROGNOSTIC DETERMINANTS IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-VE) BENIGN PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML)
    KANTARJIAN, H
    KEATING, M
    MCCREDIE, K
    WALTERS, R
    TALPAZ, M
    BERAN, M
    SMITH, T
    FREIREICH, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 151 - 151
  • [38] Philadelphia chromosome in chronic myelogenous leukemia: Confirmation of cytogenetic diagnosis in Ph positive and negative cases by fluorescence in situ hybridization
    Acar, H
    Stewart, J
    Connor, MJ
    CANCER GENETICS AND CYTOGENETICS, 1997, 94 (02) : 75 - 78
  • [39] Dasatinib population pharmacokinetics in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ph plus all)
    Dai, Guowei
    Roy, Amit
    Mandava, Mohan
    Blackwood-Chirchir, Anne
    Luo, Roger
    Wu, Chiyuan
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
  • [40] Interferon alpha (IFN-A) and low-dose cytosine arabinoside (ARA-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    Kantarjian, H
    OBrien, S
    Beran, M
    Koller, C
    Andreeff, M
    Rios, MB
    Keating, M
    Freireich, E
    Talpaz, M
    BLOOD, 1995, 86 (10) : 2105 - 2105
12345